Systemic sclerosis

Carol A. Feghali-Bostwick*, John Varga

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

A characteristic feature of systemic sclerosis (SSc) distinguishing it from other autoimmune and connective tissue diseases is the occurrence of widespread parenchymal fibrosis. SSc carries the highest case fatality rate among the connective tissue diseases. Although inflammation, autoimmunity, vascular injury, and damage are prominent early events in SSc with significant roles in the development of progressive tissue damage, fibrosis is the hallmark of the disease. Genetic and epidemiologic studies suggest that SSc occurs in susceptible individuals following exposure to (as yet uncharacterized) environmental triggers. Suppression of pro-fibrotic factor expression and/or function and induction of anti-fibrotic gene expression or activity provide complementary approaches for the prevention and/or treatment of fibrosis. Potential approaches that might be feasible for such anti-fibrotic interventions are illustrated. Several animal models of scleroderma are described, although none reproduce all the cardinal features of human SSc. Robust experimental strategies such as transgenic animal modeling and DNA microarray analysis of gene expression are beginning to yield a coherent picture. Selected novel therapeutic agents with a potential utility in the treatment of SSc-associated fibrosis are listed.

Original languageEnglish (US)
Title of host publicationHandbook of Cell Signaling, 2/e
PublisherElsevier Inc.
Pages2913-2917
Number of pages5
Volume3
ISBN (Print)9780123741455
DOIs
StatePublished - Dec 1 2010

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Systemic sclerosis'. Together they form a unique fingerprint.

Cite this